VisilizuMab
Modify Date: 2025-08-26 18:20:37
VisilizuMab structure
|
Common Name | VisilizuMab | ||
|---|---|---|---|---|
| CAS Number | 219716-33-3 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of VisilizuMabVisilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research[1]. |
| Name | VisilizuMab |
|---|---|
| Synonym | More Synonyms |
| Description | Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Visilizumab 诱导固有层 T 细胞的剂量和时间依赖性细胞凋亡。Visilizumab 诱导固有层 T 细胞凋亡依赖于半胱天冬酶 3 和 8，而不是半胱天冬酶 9 的激活，并且不涉及 Fas/FasL 通路[1]。 Apoptosis Analysis[1] Cell Line: Lamina propria T cells Concentration: 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10000 ng/mL Incubation Time: 2 hours, 4 hours, 20 hours, 24 hours, 48 hours Result: Induced dose- and time-dependent apoptosis of lamina propria T cells. |
| References |
| No Any Chemical & Physical Properties |
| VISILIZUMAB |